Dawn has over 15 years experience in the strategic development of anti-thrombotic agents including out-licensing/M&A responsibilities. She has worked on successful brands including Integrilin, Angiomax and Cangrelor. Recently she led US operations at Canyon Pharmaceuticals launching Iprivask, winner of the 2011 Frost and Sullivan Product Differentiation Award for Parenteral Anticoagulants. She earned her PharmD from the University of Florida.

Mike has 20 years experience in pre-clinical and clinical cardiovascular research. For the past 10 years he has focused on anti-thrombotic therapies including work on ReoPro, Retevase, the Cypher Stent and Iprivask. Mike earned his PhD in Physiology and Biophysics from the University of Louisville and completed two NIH-funded fellowships in cardiovascular physiology before joining Gensia to head up pre-clinical cardiovascular pharmacology.